Tagged with BI

France In recent times, French pharma industry associations have been arguing vociferously about the need to proactively ‘re-industrialise’ French pharma to counter the distortionary impact of protectionist policies and massive state subsidies in rival markets.   “France’s industrial fabric risks being systematically hollowed out if we don’t act fast to mitigate…

France France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as a benchmark internationally, and which few other countries have proven able to match.   “Back in the mid-2000s, under the…

France France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis Pasteur’s work on germ theory and pasteurisation in the 19th century laid the groundwork for much of what we know…

France When Marc de Garidel joined AbiVax as CEO in 2023, the firm had very recently teetered on the brink of bankruptcy. Now, less than three short years later, he leads the hottest prospect in European biotech, with a potentially market-leading drug for inflammatory bowel disease nearing regulatory approval. de Garidel…

Taiwan ImmunAdd’s Dr Pi-Hui Liang discusses her transition from academic research to entrepreneurship, driven by the critical shortage of commercially available vaccine adjuvants. With a proprietary saponin-based platform addressing supply chain constraints and toxicity limitations of existing adjuvants, ImmunAdd aims to democratise access to advanced immunological tools whilst developing its own…

Taiwan Dr Ethan Shen moves comfortably between the clinic, the laboratory, and capital markets, and this conversation reflects that rare vantage point. He explains how YD Bio is built not as a single-asset biotech, but as an integrated platform designed to connect diagnostics, data, and advanced therapies with real clinical execution.…

MEA Biogen’s transformation into a rare disease-focused organisation is reshaping how innovation reaches patients in the GCC. Diederik Kok, the company’s GCC Head reflects on how global strategy translates into regional execution, from launching first-in-class therapies and navigating access for ultra-rare conditions, to building sustainable financing models, clinical research capacity, and…

Global Andrea Johnston,* Senior Phorum Director at BioPhorum,** argues that the biopharma industry’s rapid embrace of digital twins is being undermined by a fundamental problem: agreeing what a digital twin actually is. Drawing on fresh benchmarking data from leading manufacturers, Johnston contends that this lack of shared definition is slowing regulatory…

USA Chris Peetz, co-founder and CEO of Mirum Pharmaceuticals, reflects on the company’s journey from rescuing overlooked rare disease programs to building a growing global pharmaceutical company. He discusses Mirum’s expanding commercial portfolio, pipeline momentum, and disciplined acquisition strategy, while emphasizing the importance of patient-centered execution in rare disease. Peetz also…

China China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. As Dr Cathy Bi of PharmaBoardroom content partner Selesta writes, while early-stage deal volume cooled, strategic liquidity remained robust for assets with mature…

France Stéphane Legastelois has spent 35 years bridging science and business. After founding Indicia, he transitioned to healthcare investing, backing 30 early-stage companies, mainly in Lyon, and now heads up 33 Californie, a boutique investment firm which combines capital with strategic guidance, de-risking start-ups before Series A financing. As he explains,…

LatAm From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that we are poised to become among the most dynamic regions for growth momentum globally driven by multiple factors: among them…